Ankündigung • May 15
Vext Science, Inc. to Report Q1, 2026 Results on May 21, 2026 Vext Science, Inc. announced that they will report Q1, 2026 results Pre-Market on May 21, 2026 Ankündigung • Mar 31
Vext Science, Inc. to Report Q4, 2025 Results on Apr 23, 2026 Vext Science, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Apr 23, 2026 Buy Or Sell Opportunity • Dec 22
Now 25% undervalued after recent price drop Over the last 90 days, the stock has fallen 10% to CA$0.30. The fair value is estimated to be CA$0.41, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.2% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 46% in 2 years. Earnings are forecast to grow by 94% in the next 2 years. New Risk • Dec 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (41% net debt to equity). Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (CA$73.1m market cap, or US$53.0m). Reported Earnings • Nov 21
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Third quarter 2025 results: US$0.011 loss per share (further deteriorated from US$0.01 loss in 3Q 2024). Revenue: US$12.7m (up 41% from 3Q 2024). Net loss: US$2.63m (loss widened 5.3% from 3Q 2024). Revenue missed analyst estimates by 5.5%. Earnings per share (EPS) also missed analyst estimates by 41%. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance. Ankündigung • Nov 11
Vext Science, Inc. to Report Q3, 2025 Results on Nov 20, 2025 Vext Science, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 20, 2025 Buy Or Sell Opportunity • Oct 15
Now 21% undervalued Over the last 90 days, the stock has risen 103% to CA$0.34. The fair value is estimated to be CA$0.44, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.1% over the last 3 years. Meanwhile, the company became loss making. Ankündigung • Oct 13
Vext Science, Inc., Annual General Meeting, Dec 11, 2025 Vext Science, Inc., Annual General Meeting, Dec 11, 2025. Buy Or Sell Opportunity • Sep 25
Now 22% undervalued Over the last 90 days, the stock has risen 113% to CA$0.34. The fair value is estimated to be CA$0.43, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.1% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Aug 21
Second quarter 2025 earnings: EPS exceeds analyst expectations Second quarter 2025 results: US$0.006 loss per share (improved from US$0.018 loss in 2Q 2024). Revenue: US$13.4m (up 59% from 2Q 2024). Net loss: US$1.48m (loss narrowed 66% from 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 31%. Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance. Ankündigung • Aug 11
Vext Science, Inc. to Report Q2, 2025 Results on Aug 20, 2025 Vext Science, Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 20, 2025 Price Target Changed • Jul 21
Price target increased by 8.7% to CA$0.72 Up from CA$0.67, the current price target is an average from 2 analysts. New target price is 326% above last closing price of CA$0.17. Stock is down 32% over the past year. The company is forecast to post a net loss per share of US$0.043 next year compared to a net loss per share of US$0.093 last year. Buy Or Sell Opportunity • Jul 07
Now 27% undervalued Over the last 90 days, the stock has risen 3.3% to CA$0.15. The fair value is estimated to be CA$0.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. New Risk • May 30
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (CA$35.6m market cap, or US$25.9m). Reported Earnings • May 22
First quarter 2025 earnings: EPS and revenues exceed analyst expectations First quarter 2025 results: US$0.013 loss per share (improved from US$0.028 loss in 1Q 2024). Revenue: US$11.6m (up 38% from 1Q 2024). Net loss: US$3.33m (loss narrowed 47% from 1Q 2024). Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) also surpassed analyst estimates by 31%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance. Ankündigung • May 13
Vext Science, Inc. to Report Q1, 2025 Results on May 21, 2025 Vext Science, Inc. announced that they will report Q1, 2025 results Pre-Market on May 21, 2025 Ankündigung • Apr 01
Vext Science, Inc. (CNSX:VEXT) acquired the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC. Vext Science, Inc. (CNSX:VEXT) acquired the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC on March 26, 2025. Vext Science utilize a non-cash consideration in the transaction. For the period end date December 31, 2024, Vapen Kentucky, LLC reported $46.3 million revenue and $3.3 million net assets based on the equity accounted investment of Vext Science.
Vext Science, Inc. (CNSX:VEXT) completed the acquisition of the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC on March 26, 2025. Reported Earnings • Mar 31
Full year 2024 earnings released: US$0.093 loss per share (vs US$0.027 profit in FY 2023) Full year 2024 results: US$0.093 loss per share (down from US$0.027 profit in FY 2023). Revenue: US$36.0m (up 3.4% from FY 2023). Net loss: US$22.4m (down US$26.8m from profit in FY 2023). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance. Ankündigung • Mar 20
Vext Science, Inc. to Report Q4, 2024 Results on Mar 31, 2025 Vext Science, Inc. announced that they will report Q4, 2024 results at 9:30 AM, US Eastern Standard Time on Mar 31, 2025 New Risk • Nov 23
New major risk - Revenue and earnings growth Earnings have declined by 10% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 10% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (CA$47.0m market cap, or US$33.6m). Reported Earnings • Nov 23
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: US$0.01 loss per share. Revenue: US$8.99m (up 11% from 3Q 2023). Net loss: US$2.50m (loss widened 36% from 3Q 2023). Revenue missed analyst estimates by 2.7%. Earnings per share (EPS) also missed analyst estimates by 40%. Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. New Risk • Nov 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (CA$48.2m market cap, or US$34.2m). Ankündigung • Nov 07
Vext Science, Inc. to Report Q3, 2024 Results on Nov 21, 2024 Vext Science, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 21, 2024 Ankündigung • Oct 15
Vext Science, Inc., Annual General Meeting, Dec 13, 2024 Vext Science, Inc., Annual General Meeting, Dec 13, 2024. Price Target Changed • Oct 06
Price target decreased by 14% to CA$0.57 Down from CA$0.67, the current price target is an average from 2 analysts. New target price is 161% above last closing price of CA$0.22. Stock is down 23% over the past year. The company is forecast to post a net loss per share of US$0.09 compared to earnings per share of US$0.027 last year. Reported Earnings • Aug 21
Second quarter 2024 earnings released: US$0.018 loss per share (vs US$0.004 profit in 2Q 2023) Second quarter 2024 results: US$0.018 loss per share (down from US$0.004 profit in 2Q 2023). Revenue: US$8.43m (down 8.3% from 2Q 2023). Net loss: US$4.39m (down US$4.93m from profit in 2Q 2023). Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings. Ankündigung • Aug 09
Vext Science, Inc. to Report Q2, 2024 Results on Aug 20, 2024 Vext Science, Inc. announced that they will report Q2, 2024 results at 9:30 AM, US Eastern Standard Time on Aug 20, 2024 Price Target Changed • Jul 01
Price target increased by 12% to CA$0.75 Up from CA$0.67, the current price target is an average from 4 analysts. New target price is 226% above last closing price of CA$0.23. Stock is down 12% over the past year. The company posted earnings per share of US$0.027 last year. Recent Insider Transactions • Jun 09
Chief Financial Officer recently bought CA$63k worth of stock On the 3rd of June, Trevor Smith bought around 247k shares on-market at roughly CA$0.26 per share. This transaction increased Trevor's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Trevor's only on-market trade for the last 12 months. Ankündigung • May 26
Vext Science, Inc. to Report Q1, 2024 Results on May 29, 2024 Vext Science, Inc. announced that they will report Q1, 2024 results Pre-Market on May 29, 2024 New Risk • May 12
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 129% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (13% net profit margin). Market cap is less than US$100m (CA$74.9m market cap, or US$54.8m). Ankündigung • Apr 16
Vext Science, Inc. to Report Q4, 2023 Results on Apr 25, 2024 Vext Science, Inc. announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Apr 25, 2024 New Risk • Mar 18
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 64% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.2x net interest cover). Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CA$68.7m market cap, or US$50.7m). Ankündigung • Jan 17
Vext Science, Inc. Announces Transition of Jason Thai Nguyen Out of Executive Role Vext Science, Inc. announced that Jason Thai Nguyen has transitioned out of his executive positions with the Company, including resigning from all positions with the Company's subsidiaries and affiliates. Mr. Nguyen will continue to serve the Company through his position as a director of the Company and Chairman of the board of directors. Reported Earnings • Nov 29
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2023 results: US$0.012 loss per share (down from US$0.003 profit in 3Q 2022). Revenue: US$8.10m (up 5.6% from 3Q 2022). Net loss: US$1.84m (down US$2.26m from profit in 3Q 2022). Revenue missed analyst estimates by 12%. Earnings per share (EPS) exceeded analyst estimates by 32%. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Ankündigung • Nov 22
Vext Science, Inc. to Report Q3, 2023 Results on Nov 28, 2023 Vext Science, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 28, 2023 Ankündigung • Oct 14
Vext Science, Inc., Annual General Meeting, Dec 15, 2023 Vext Science, Inc., Annual General Meeting, Dec 15, 2023. New Risk • Oct 13
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 57% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (CA$56.5m market cap, or US$41.4m). Ankündigung • Oct 13
Vext Science, Inc. announced that it has received $11.5 million in funding from LLF Financial S.A. On October 12, 2023, Vext Science, Inc. closed the transaction. The company has now issued 67,647,058 common shares at a price of $0.17 per share for the gross proceeds of $11,500,000. In connection with the offering, the company has paid a cash finder's fee to certain registered dealers consisting of approximately $3,285. The transaction included participation from Mark Opzoomer, Trevor Smith and Sopica Special Opportunities Fund Limited managed by LLF Financial S.A. for 42,798,529 shares. Sopica Special Opportunities Fund Limited purchased 41,176,470 subordinate voting shares for $7,000,000 and its stake is increased by 21.56% (from 13.00% to 34.56%) on a non-diluted basis. Immediately prior to the Private Placement, the Acquirors beneficially owned or otherwise exercised control or direction over 10,726,849 Subordinate Voting Shares, 4,303,182 warrants to purchase Subordinate Voting Shares and 112,486 Class A common shares, representing approximately 26.79% of the issued and outstanding Subordinate Voting Shares. As a result of the Private Placement, the Acquirors beneficially own or otherwise exercise control or direction over 51,903,319 Subordinate Voting Shares, 4,303,182 Warrants and 112,486 Multiple Voting Shares, representing approximately 40.70% of the issued and outstanding Subordinate Voting Shares as at October 12, 2023. Reported Earnings • Aug 24
Second quarter 2023 earnings: EPS exceeds analyst expectations Second quarter 2023 results: EPS: US$0.004 (down from US$0.014 in 2Q 2022). Revenue: US$9.19m (up 4.8% from 2Q 2022). Net income: US$535.5k (down 73% from 2Q 2022). Profit margin: 5.8% (down from 22% in 2Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 42% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Ankündigung • Aug 18
Vext Science, Inc. to Report Q2, 2023 Results on Aug 23, 2023 Vext Science, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 23, 2023 Reported Earnings • May 27
First quarter 2023 earnings released: EPS: US$0 (vs US$0.016 in 1Q 2022) First quarter 2023 results: EPS: US$0 (down from US$0.016 in 1Q 2022). Revenue: US$9.11m (down 16% from 1Q 2022). Net income: US$73.1k (down 97% from 1Q 2022). Profit margin: 0.8% (down from 21% in 1Q 2022). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Ankündigung • May 16
Vext Science, Inc. to Report Q1, 2023 Results on May 25, 2023 Vext Science, Inc. announced that they will report Q1, 2023 results Pre-Market on May 25, 2023 Price Target Changed • May 10
Price target increased by 7.2% to CA$1.30 Up from CA$1.21, the current price target is an average from 3 analysts. New target price is 341% above last closing price of CA$0.29. Stock is down 30% over the past year. The company posted earnings per share of US$0.079 last year. Reported Earnings • Mar 23
Full year 2022 earnings released: EPS: US$0.079 (vs US$0.036 in FY 2021) Full year 2022 results: EPS: US$0.079 (up from US$0.036 in FY 2021). Revenue: US$35.4m (down 4.9% from FY 2021). Net income: US$10.9m (up 119% from FY 2021). Profit margin: 31% (up from 13% in FY 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Board Change • Dec 21
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Mark Opzoomer was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Dec 17
Vext Science, Inc. (CNSX:VEXT) entered into agreement to acquire Appalachian Pharm Processing, LLC for $12.5 million. Vext Science, Inc. (CNSX:VEXT) entered into agreement to acquire Appalachian Pharm Processing, LLC for $12.5 million on December 15, 2022. Consideration an aggregate of $750,000 in cash paid upon execution of the Purchase Agreements, an aggregate of $3.0 million principal amount of unsecured promissory notes, an aggregate of approximately $6 million principal amount of unsecured promissory notes to be issued by Vapen Ohio on the earlier of (i) closing of the Proposed APP Acquisitions and (ii) January 1, 2023, an aggregate of 8,999,989 Common Shares, at a deemed price of $0.156 per share, issued upon execution of the Purchase Agreements subject to certain customary adjustments. The Proposed APP Acquisition is subject to regulatory approvals and other customary conditions precedent. Proposed Transaction are expected to close by the end of the second quarter of 2023. Eight Capital acted as financial advisor to Vext and its board of directors. McMillan LLP acted as legal counsel to Vext and Bianchi & Brandt acted as legal counsel to Vext. Gordon Bibart, LLC acted as legal counsel to APP. Eight Capital acted as Fairness Opinion Provider to Vext. Ankündigung • Dec 16
Vext Science, Inc. Announces Board Changes Vext Science, Inc. announced that the Board has accepted the resignation of Mr. David Eaton from the Board effective December 15, 2022 and after the Company's Annual General Meeting. In conjunction with Mr. Eaton's departure, Mr. David Johns has been appointed to the Board, effective December 15, 2022. Mr. Johns has demonstrated experience in the services and IT industry and sits on the boards of several companies. He is currently the Managing Director of APP in Ohio, which produces THC and CBD infused medical marijuana products for patients across the state. Prior to joining APP, David was the SVP and CIO at Ascena Retail Group Inc, where he successfully implemented large-scale IT transformation and project efforts. Previously, David led the Global Information Technology, Global Business Shared Services and Corporate Services Sourcing functions at Owens Corning. He joined Owens Corning in 1994, and in this latest role as SVP and CIO, David had oversight for all Owens Corning business shared service centers, manufacturing technology, project portfolio management, sourcing and information systems. Prior to his experience at Owens Corning, David held technology positions with Honeywell, Inc. and Time Warner. In both of these roles, he orchestrated major computer systems development and management activities at both the division and corporate levels. David holds a Bachelor of Science in Computer Science Engineering from The Ohio State University and a Master of Business Administration from the University of Dayton. David was a scholarship athlete while at The Ohio State University. He was inducted into the CIO Hall of Fame in 2009 and was named one of Computerworld's Premier 100 information technology leaders for 2012. Price Target Changed • Nov 23
Price target decreased to CA$1.24 Down from CA$1.46, the current price target is an average from 4 analysts. New target price is 450% above last closing price of CA$0.23. Stock is down 70% over the past year. The company posted earnings per share of US$0.036 last year. Reported Earnings • Nov 19
Third quarter 2022 earnings released: EPS: US$0.003 (vs US$0.007 in 3Q 2021) Third quarter 2022 results: EPS: US$0.003 (down from US$0.007 in 3Q 2021). Revenue: US$7.67m (down 18% from 3Q 2021). Net income: US$423.5k (down 56% from 3Q 2021). Profit margin: 5.5% (down from 10% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Nov 11
Vext Science, Inc. to Report Q3, 2022 Results on Nov 17, 2022 Vext Science, Inc. announced that they will report Q3, 2022 results Pre-Market on Nov 17, 2022 Price Target Changed • Oct 25
Price target decreased to CA$1.46 Down from CA$1.58, the current price target is an average from 4 analysts. New target price is 396% above last closing price of CA$0.29. Stock is down 63% over the past year. The company posted earnings per share of US$0.036 last year. Ankündigung • Oct 15
Vext Science, Inc., Annual General Meeting, Dec 15, 2022 Vext Science, Inc., Annual General Meeting, Dec 15, 2022. Ankündigung • Sep 21
Vext Science Announces Filing of Provisional Patent Application Vext Science, Inc. announced that its research and development team has filed a provisional patent application (the "Patent") with the United States Patent Office ("USPTO") in collaboration with researchers at BioSciTech and Arizona State University ("ASU"). The patent covers new crystalline forms of phytocannabinoid acids, a class of non-psychoactive natural products isolated from the cannabis sativa plant, several of which have been proven to be pharmaceutically active. Crystallized phytocannabinoids have been proven to be the most effective method to ensure pharmaceutical level purity for processing and production. These crystalline forms also have improved shelf-life and bioavailability compared to the natural forms. Studies have also indicated that phytocannabinoid acids have anti-inflammatory properties, and may be applicable as anti-virals. Ankündigung • Sep 16
Sopica Special Opportunities Fund Limited, managed by LLF Financial S.A. acquired a 13.65% stake in Vext Science, Inc. (CNSX:VEXT) from Jason T. Nguyen for $3 million. Sopica Special Opportunities Fund Limited, managed by LLF Financial S.A. entered into a share purchase agreement to acquire a 13.65% stake in Vext Science, Inc. (CNSX:VEXT) from Jason T. Nguyen for $3 million on September 3, 2022. Sopica purchased 112,486 Class A Multiple Voting Shares at a price of $26.67 per share, representing 16.72% of the issued and outstanding Multiple Voting Shares and 13.65% of the issued and outstanding common shares of VEXT (assuming conversion of the acquired Multiple Voting Shares). Immediately prior to the Transaction, Nguyen beneficially owned or otherwise exercised control or direction over 605,747 Multiple Voting Shares, 1,425,300 Subordinate Voting Shares and 100,000 options to purchase Subordinate Voting Shares (“Options”), representing approximately 90.04% of the issued and outstanding Multiple Voting Shares and approximately 47.07% of the issued and outstanding Subordinate Voting Shares (on an a partially diluted basis). As a result of the Transaction, Nguyen beneficially owns or otherwise exercises control or direction over 493,261 Multiple Voting Shares, 1,425,300 Subordinate Voting Shares and 100,000 Options, representing approximately 73.32% of the issued and outstanding Multiple Voting Shares and approximately 42.12% of the issued and outstanding Subordinate Voting Shares (on a partially diluted basis).
Sopica Special Opportunities Fund Limited, managed by LLF Financial S.A. completed the acquisition of a 13.65% stake in Vext Science, Inc. (CNSX:VEXT) from Jason T. Nguyen on September 14, 2022. Reported Earnings • Aug 25
Second quarter 2022 earnings released: EPS: US$0.014 (vs US$0.013 in 2Q 2021) Second quarter 2022 results: EPS: US$0.014 (up from US$0.013 in 2Q 2021). Revenue: US$8.77m (down 6.5% from 2Q 2021). Net income: US$1.95m (up 8.9% from 2Q 2021). Profit margin: 22% (up from 19% in 2Q 2021). The increase in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 31%, compared to a 24% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Aug 24
Director recently bought CA$53k worth of stock On the 16th of August, Mark Opzoomer bought around 125k shares on-market at roughly CA$0.42 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$95k more in shares than they have sold in the last 12 months. Ankündigung • Aug 23
Vext Science, Inc. to Report Q2, 2022 Results on Aug 24, 2022 Vext Science, Inc. announced that they will report Q2, 2022 results After-Market on Aug 24, 2022 Ankündigung • Jun 16
Vext Science, Inc. Announces CFO Transition Vext Science, Inc. announced that current Chief Financial Officer Daniel Engel, has decided to leave the Company to pursue an opportunity with a private equity backed company. Stephan Bankosz will take over as Vext's interim CFO and Corporate Secretary while the Company considers internal and external candidates. Mr. Bankosz was appointed CFO of New Gen Holdings, Inc., ("New Gen"), Vext's primary operating subsidiary, in January 2021. Additional finance resources will be recruited under Stephan to support Vext's growth plans. Mr. Bankosz has over 25 years experience in financial management, operational control and riskmanagement at leading manufacturing and distribution companies throughout the United States. His proven expertise in managing corporate profitability for growth companies has been valuable since his appointment as CFO of New Gen in January 2021, and will continue to be beneficial as Vext continues to execute its growth plans in Arizona and Ohio. Mr. Bankosz holds a Bachelor's degree in accounting and management information systems and is a Microsoft Certified Systems Engineer, with specialized certification in over 20 accounting and distribution programs. Reported Earnings • Jun 02
First quarter 2022 earnings released First quarter 2022 results: Revenue: US$10.8m (up 18% from 1Q 2021). Net income: US$3.46m (up 204% from 1Q 2021). Profit margin: 32% (up from 12% in 1Q 2021). The increase in margin was primarily driven by higher revenue. Over the next year, revenue is forecast to grow 21%, compared to a 92% growth forecast for the industry in Canada. Ankündigung • May 27
Vext Science, Inc. to Report Q1, 2022 Results on May 30, 2022 Vext Science, Inc. announced that they will report Q1, 2022 results After-Market on May 30, 2022 Price Target Changed • Apr 27
Price target decreased to CA$1.84 Down from CA$1.99, the current price target is an average from 4 analysts. New target price is 338% above last closing price of CA$0.42. Stock is down 58% over the past year. The company posted earnings per share of US$0.036 last year. Board Change • Apr 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director David Eaton is the most experienced director on the board, commencing their role in 2015. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Apr 22
Full year 2021 earnings released: EPS: US$0.036 (vs US$0.023 in FY 2020) Full year 2021 results: EPS: US$0.036 (up from US$0.023 in FY 2020). Revenue: US$37.2m (up 48% from FY 2020). Net income: US$4.99m (up 135% from FY 2020). Profit margin: 13% (up from 8.4% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 17%, compared to a 108% growth forecast for the pharmaceuticals industry in Canada. Ankündigung • Apr 21
Vext Science, Inc. Announces Executive Changes Vext Science, Inc. announced that senior financial and operations executive Daniel Engel will join the Company on May 2, 2022, as the Company's CFO. Current CFO Vahan Ajamian will be staying for a planned transition period through May 31, 2022. Ankündigung • Apr 15
Vext Science, Inc. to Report Q4, 2021 Results on Apr 20, 2022 Vext Science, Inc. announced that they will report Q4, 2021 results Pre-Market on Apr 20, 2022 Price Target Changed • Apr 04
Price target decreased to CA$1.99 Down from CA$2.25, the current price target is an average from 3 analysts. New target price is 231% above last closing price of CA$0.60. Stock is down 36% over the past year. The company posted earnings per share of US$0.023 last year. Board Change • Feb 12
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director David Eaton is the most experienced director on the board, commencing their role in 2015. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Ankündigung • Feb 11
Vext Science, Inc. Appoints Mark W. Opzoomer as Board of Director Vext Science, Inc. announced that Mark W. Opzoomer, a highly experienced global executive and director, has been appointed to the Company's board of directors effective immediately. Mr. Opzoomer is currently Managing Director at Bond Capital Partners, a mid-market private equity investor and advisory firm, which he founded in 2004. Mr. Opzoomer is also currently Chairman of Trint Limited (SaaS AI media creation workflow platform) and a director of the Mark'ennovy group (R&D driven custom contact lens maker and marketer). Mark recently stepped down as Chairman of Somo Global Ltd. in January on the successful sale to CI&T Inc, both leaders in digital transformation services. Mark served 12 years on the board of Entertainment One Ltd. before its $3.8 billion acquisition by Hasbro Inc. in December 2019, latterly as Senior Independent Director, and included three-year periods as Chair of each of the Audit Committee and Remuneration Committee. Reported Earnings • Nov 20
Third quarter 2021 earnings released The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: US$9.40m (up 18% from 3Q 2020). Net income: US$970.1k (down 31% from 3Q 2020). Profit margin: 10% (down from 18% in 3Q 2020). The decrease in margin was driven by higher expenses. Reported Earnings • Aug 25
Second quarter 2021 earnings released The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$9.38m (up 39% from 2Q 2020). Net income: US$1.79m (up 222% from 2Q 2020). Profit margin: 19% (up from 8.3% in 2Q 2020). The increase in margin was driven by higher revenue.